Viewing Study NCT01688960


Ignite Creation Date: 2025-12-25 @ 2:16 AM
Ignite Modification Date: 2025-12-26 @ 12:45 AM
Study NCT ID: NCT01688960
Status: COMPLETED
Last Update Posted: 2015-03-17
First Post: 2012-09-17
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Sponsor: Regeneron Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module